TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Island Pharmaceuticals Ltd ( (AU:ILA) ).
Island Pharmaceuticals Ltd announced promising results from studies on their antiviral drug, Galidesivir, which showed a 94% survival rate in Marburg-infected primates and a 100% survival rate in Ebola-infected primates when administered promptly. These findings support the company’s strategy to engage with the FDA for fast-track approval under the Animal Rule, potentially enhancing its market position as a key provider of antiviral solutions for government stockpiles.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on creating treatments for high-priority viral threats. The company is working on positioning its product, Galidesivir, as a critical countermeasure for inclusion in government stockpiles.
Average Trading Volume: 616,305
Technical Sentiment Signal: Buy
Current Market Cap: A$78.67M
For an in-depth examination of ILA stock, go to TipRanks’ Overview page.